|
CLCC1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.24050000563869E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.05330000055304E-07 |
| Normal-vs-Stage2 |
3.277500E-03 |
| Normal-vs-Stage3 |
3.48990003562477E-09 |
| Normal-vs-Stage4 |
1.27020000073585E-08 |
| Stage1-vs-Stage2 |
1.477040E-01 |
| Stage1-vs-Stage3 |
9.787900E-02 |
| Stage1-vs-Stage4 |
1.073040E-01 |
| Stage2-vs-Stage3 |
1.485550E-02 |
| Stage2-vs-Stage4 |
1.187880E-02 |
| Stage3-vs-Stage4 |
7.518800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.35560007663571E-10 |
| Normal-vs-AfricanAmerican |
3.960600E-01 |
| Normal-vs-Asian |
1.30149999999496E-07 |
| Caucasian-vs-AfricanAmerican |
5.584900E-04 |
| Caucasian-vs-Asian |
8.111000E-01 |
| AfricanAmerican-vs-Asian |
1.133590E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.63869999978562E-07 |
| Normal-vs-Female |
4.92079998970496E-09 |
| Male-vs-Female |
8.371600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.38579999978228E-07 |
| Normal-vs-Age(41-60Yrs) |
5.5552999977948E-08 |
| Normal-vs-Age(61-80Yrs) |
3.55850000022251E-07 |
| Normal-vs-Age(81-100Yrs) |
2.464500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.937600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.310400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.115000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.164000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.954600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.125000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.30680000551575E-08 |
| Classical-VS-Follicular |
1.006020E-02 |
| Classical-VS-Other |
9.773600E-02 |
| Classical-VS-Normal |
1.04359999530956E-08 |
| Tall-VS-Follicular |
1.05649999859736E-09 |
| Tall-VS-Other |
6.375200E-01 |
| Tall-VS-Normal |
1.66533453693773E-15 |
| Follicular-VS-Other |
3.129900E-02 |
| Follicular-VS-Normal |
5.802800E-03 |
| Other-VS-Normal |
9.6847000000011E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.05740000003285E-06 |
| Normal-vs-N1 |
1.95119476131822E-11 |
| N0-vs-N1 |
6.787600E-04 |
|
|
